9:00 AM
ALERT :: Sun Pharma enters into a non-exclusive patent licensing agreement with Takeda Pharmaceutical
Sun Pharma and includes its subsidiaries and/or associate companies) today announced that it has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited to commercialise Vonoprazan tablets 10 mg, 20 mg in India under the brand name “Voltapraz”.Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders.
Under the terms of this agreement, Takeda has granted Sun Pharma non-exclusive patent licensing rights for the commercialization of Vonoprazan in India.
8:55 AM
Budget 2024-25: New income tax regime may offer a treat to salaried class
Amid the Budget preparation, the revenue department is assessing the feasibility of further adjustments to maximise benefits for salaried individuals. “Gradually transitioning to a predictable tax regime with minimal rates and phasing out deductions and exemptions have always been the intention, and will be a central focus in the review process, which could potentially include changes in tax rates,” an official familiar with discussions on the matter told Business Standard. READ MORE
Sebi tightens norms for IPO price discovery to curb manipulation
In certain cases of IPOs and relisted scrips, the market regulator observed that though orders were being placed at higher price in large volumes during the call auction, a significant portion of these orders were cancelled just before the session closed. This led to false demand and supply, leading to possible manipulation of prices of the scrips. READ MORE
